RPRX vs SRE · P/E 15, rev $1.30B vs P/E 31, rev $13.70B
Royalty Pharma Plc (RPRX) versus Sempra Energy (SRE) — a side-by-side from cached financials, not a winner call.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Sempra Energy (SRE) is a utilities - diversified company listed on US.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Latest reported SRE revenue for 2025-12-31 was $13.70B. Net income was $1.84B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
RPRX currently screens at market cap $20.45B and trailing P/E 14.8. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
Not investment advice. Open the RPRX and SRE stock pages for the full models.
Not investment advice.